The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial

Expert Opinion on Biological Therapy

Volumn 14, Issue 6, 2014, Pages 749-756

  Al Mutairi, Nawaf ^a   Nour, Tarek ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b FARWANIYA HOSPITAL   (Kuwait)

Author keywords

Biologics; Obesity; Psoriasis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; BODY SURFACE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; OBESITY; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BODY MASS; CALORIC RESTRICTION; COMPLICATION; DIET THERAPY; IMMUNOLOGY; KUWAIT; METABOLISM; MIDDLE AGED; PSORIASIS; REMISSION; SEVERITY OF ILLNESS INDEX; TIME; WAIST CIRCUMFERENCE; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL PRODUCTS; BODY MASS INDEX; CALORIC RESTRICTION; DERMATOLOGIC AGENTS; FEMALE; HUMANS; KUWAIT; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; PSORIASIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WAIST CIRCUMFERENCE; WEIGHT LOSS; YOUNG ADULT;

EID: 84900823222     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.900541     Document Type: Article

References (52)

1. Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006;212:327-37
2. Barker J. Skin diseases with high public health impact. Psoriasis. Eur J Dermatol 2007;17:563-4
3. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6
4. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012;132:556-62
5. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Derm Treat 2005;16:319-23
6. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152-5
7. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol 2010;37(2):146-55
8. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125(1):61-7
9. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' Health Study II. Arch Intern Med 2007;167(15):1670-5
10. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35
11. Naldi L, Parazzini F, Peli L, et al. Dietary factors and the risk of psoriasis. Results of an Italian case-control study. Br J Dermatol 1996;134(1):101-6
12. Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 2005;64:1137-40
13. Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 2005;90:3510-16
14. Gisondi P, Cotena C, Tessari G, et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008;22:341-4
15. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008;57:290-5
16. Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther 2011;24:446-51
17. Gisondi P, Conti A, Galdo G, et al. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013;168:1124-7
18. Mahé E, Reguiai Z, Barthelemy H, et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol 2012. [Epub ahead of print]
19. Tan E, Baker C, Foley P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Australas J Dermatol 2013;54(4):259-63
20. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011;25:1007-11
21. Florin V, Cottencin AC, Delaporte E, Staumont-Sallé D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol 2013;27:e186-90
22. Argiles JM, Lopez-Soriano FJ, Busquets S. Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 2012;17:253-62
23. Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of antitumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006;84:1463-72
24. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 2007;46:1824-7
25. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33:1447-51
26. Rucević I, Perl A, Barisic-Drusko V, Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol 2003;27(Suppl 1):41-8
27. Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA 2013;149(7):795-801
28. Pérez-Pérez L, Allegue F, Caeiro JL, Zulaica JM. Severe psoriasis, morbid obesity and bariatric surgery. Clin Exp Dermatol 2009;34(7):e421-2
29. Higa-Sansone G, Szomstein S, Soto F, et al. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004;14(8):1132-4
30. Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves psoriasis. J Am Acad Dermatol 2011;65(1):198-200
31. Lindegaard B. Diseases associated with psoriasis in a general population of 159, 200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304
32. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-34
33. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559-65
34. Clark L, Lebwohl M. The effect of weight on the efficacy of biologictherapy in patients with psoriasis. J Am Acad Dermatol 2008;58:443-6
35. Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010;63(4):571-9
36. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112(12):1796-808
37. Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator blinded clinical trial. Am J Clin Nutr 2008;88(5):1242-7
38. Farias MM, Achurra P, Boza C, et al. Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. Obes Surg 2012;22(6):877-80
39. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011;20:81-7
40. Papadavid E, Vlami K, Dalamaga M, et al. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role? J Eur Acad Dermatol Venereol 2013;27(7):820-6
41. Caglia MT, Krueger GG. Psoriasis and the obesity epidemic: the effect of weight loss. JAMA Dermatol 2013;149(7):786-7
42. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15
43. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005;2005:273-9
44. Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010;24(12):1386-94
45. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008;159(5):1207-8
46. Mattioli B, Straface E, Quaranta MG, et al. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol 2005;174:6820-8
47. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006;67(4):768-73
48. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5
49. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-19
50. Sterry W, Strober BE, Menter A; International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-55
51. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-51
52. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008;159:342-50